Application of Jinbei preparation in resisting coronavirus

A coronavirus and preparation technology, applied in the field of medicine, can solve the problems of no obvious effect of the virus, aggravation of infection, secondary fungal infection, etc., and achieve the effect of shortening the time of nucleic acid turning negative, preventing pulmonary fibrosis, and preventing the deterioration of the disease

Inactive Publication Date: 2020-09-18
山东宏济堂制药集团股份有限公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hormones can reduce the inflammatory response of the lungs, which is beneficial to improve the symptoms of hypoxia and respiratory distress, but it can also suppress the immune function of the body, which may lead to the spread of the virus; in addition, when the infection is not controlled, the application of hormones may lead to the aggravation of the infection. The use of high-dose hormones may cause serious complications such as gastrointestinal bleeding and secondary fungal infections; during the SARS virus epidemic in 2003, during the clinical first-line treatment of critically ill patients, the use of large doses of hormones saved the lives of many patients, and at the same time, many Side effects and sequelae, such as gastrointestinal bleeding, pulmonary fibrosis, femoral head necrosis, etc.
Antibiotics are aimed at bacteria, have no obvious effect on viruses, and are prone to drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Jinbei preparation in resisting coronavirus
  • Application of Jinbei preparation in resisting coronavirus
  • Application of Jinbei preparation in resisting coronavirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] 1. Purpose

[0039] Evaluate the anti-2019-nCoV effect of Jinbei oral liquid laboratory antibody at the cellular level (CPE, PFU).

[0040] . Experimental Materials

[0041] Test drug: Jinbei Oral Liquid. The concentration of the tested drug was determined by the toxicity test.

[0042] Table 1 Composition of Jinbei Oral Liquid

[0043]

[0044] Cells: Vero cells, preserved by the Cell Bank of the Institute of Microbiology and Epidemiology.

[0045]Virus: 2019-nCoV, with a titer of 107CCID50 / ml, stored in the virus bank of the Institute of Microbiology and Epidemiology and the P3 virus seed refrigerator at -80°C. Use a virus titer of 100CCID50 / well.

[0046] . experimental method:

[0047] 3.1 Test drug cytotoxicity test (CPE):

[0048] 3.1.1 Test operation

[0049] (1) In a sterile 96-well culture plate, add 100µl of Vero cells at a concentration of 1×105cell / ml to each well, and incubate at 37°C with 5% CO2 for 24 hours;

[0050] (2) 5 concentrations of...

Embodiment 2

[0085] 1. Purpose

[0086] Evaluation of the anti-SARS-CoV virus effect of Jinbei Oral Liquid at the cellular level.

[0087] Experimental Materials

[0088] Test drug: Jinbei Oral Liquid. The concentration of the tested drug was determined by the toxicity test. The composition of the drug is shown in Table 4.

[0089] Table 4 Composition of Jinbei Oral Liquid

[0090]

[0091] Cells: Vero E6 cells, preserved by the Cell Bank of the Institute of Microbiology and Epidemiology.

[0092] Cell culture medium: containing 10% calf serum, 0.29mg% glutamine, sodium bicarbonate 2mg / ml.

[0093] Virus maintenance solution: containing 2% calf serum, 0.29mg% glutamine, sodium bicarbonate 2mg / ml.

[0094] Virus: SARS Vinis, derived from Vero E6 cells.

[0095] . experimental method:

[0096] 3.1 Determination of drug toxicity Same as in Example 1.

[0097] Test drug: Jinbei Oral Liquid, drug concentration (1 non-toxic highest concentration): 1:100

[0098] 3.2 Antiviral expe...

Embodiment 3

[0112] 1. Test topic

[0113] A clinical trial on the effectiveness of Jinbei Oral Liquid in the treatment of novel coronavirus (COVID-19) pneumonia.

[0114] . Approval Number

[0115] Lu Yao Zi Z20200001

[0116] 3. Laboratory

[0117] Wuhan Third Hospital (Optics Valley Campus)

[0118] 4. Test start and end time

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine, and particularly relates to application of a Jinbei preparation in resisting coronavirus. The Jinbei preparation has inhibitory effects on the novel coronavirus (2019-nCoV) and SARS-CoV, can effectively inhibit the proliferation of 2019-nCoV and SARS-CoV in in vitro tests, has high therapeutic indexes for the 2019-nCoV and SARS-CoV, can reduce the degree of CPE lesions significantly and has good effects. The 15-day clinical observation results show that the Jinbei preparation is clinically effective in treating mild and common novel coronavirus pneumonia; the combined use of the Jinbei preparation and chemicals can shorten the time for patients with novel coronavirus pneumonia to turn negative, and the time for fatigue and cough to return tonormal, reduce patient temperature fluctuations during treatment and significantly shorten the effective days of treatment for patients with novel coronavirus pneumonia.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of Jinbei preparation in anti-coronavirus. Background technique [0002] In terms of systematic classification, coronaviruses belong to the order Nidovirales, the family Coronaviridae, and the genus Coronavirus. Viruses of the genus Coronavirus are RNA viruses with an envelope and a linear single-stranded positive strand genome. They are a large class of viruses that exist widely in nature. [0003] The diameter of coronavirus is about 80-120nm, the 5′ end of the genome has a methylated cap structure, and the 3′ end has a poly(A) tail. The total length of the genome is about 27-32kb. . [0004] Coronavirus was first isolated from chickens in 1937. The diameter of virus particles is 60-200nm, with an average diameter of 100nm, spherical or oval, and pleomorphic. The virus has an envelope, and there are spines on the envelope. The whole virus is like a corona,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/8966A61P31/14A61P11/00A61P29/00A61P11/14
CPCA61K36/481A61K36/344A61K36/23A61K36/537A61K36/232A61K36/236A61K36/355A61K36/634A61K36/539A61K36/8888A61K36/8966A61K36/484A61P31/14A61P11/00A61P29/00A61P11/14A61K2300/00
Inventor 张爱均孟兆青陶凯张良棕丁琳严嘉伟王俊廉李樱王丽丽黄蒙蒙
Owner 山东宏济堂制药集团股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap